New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 3, 2014
18:56 EDTSNY, GSK, KKRPE firms mull combining older GSK, Sanofi drug brands, FT says
Private equity firms including KKR (KKR) and Warburg Pincus are considering purchasing the older drug portfolios of GlaxoSmithKline (GSK) and Sanofi (SNY) and combining them, says the Financial Times. Reference Link
News For GSK;SNY;KKR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
09:14 EDTGSKAdamis says albuterol HFA product study met clinical FEV1 primary endpoint
Subscribe for More Information
08:15 EDTGSKGlaxoSmithKline and Theravance announce launch of Anoro in Spain
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Anoro in Spain following the approval in Europe in May 2014. Anoro Ellipta is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro Ellipta is a combination of two bronchodilators, umeclidinium, a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, in a single dry powder inhaler, the Ellipta. The approved dose of UMEC/VI is 55/22mcg. UMEC/VI has been developed under the 2002 LABA collaboration agreement between Glaxo Group Limited and Theravance.
08:03 EDTKKRKKR closes $1.34B direct lending fund
Subscribe for More Information
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
11:53 EDTGSKGlaxoSmithKline initiated with a Sell at Societe Generale
07:41 EDTSNYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
13:02 EDTKKRFly Watch: Analyst expects strong Q1 results from private equity firms
Subscribe for More Information
10:00 EDTKKRGroupon core business still key to valuation, says Piper Jaffray
Subscribe for More Information
08:27 EDTKKRPrivate equity business model strong, results likely strong, says Oppenheimer
Oppenheimer's analyst says that private equity's business model is the best one he has seen in 30 years of following financial stocks. The firm expects most of the companies in the sector to report strong Q1 results, and predicts that investors will gain confidence in the sustainability of private equity firms' businesses. Oppenheimer identifies Crane (CR) and KKR (KKR) as its favorite names in the sector.
08:04 EDTKKRKKR names Luis Tellez as senior advisor
Subscribe for More Information
07:00 EDTKKRKKR investor consortium close to deal to buy stake in Ticket Monster, WSJ says
Subscribe for More Information
April 9, 2015
18:11 EDTKKRUniCredit, KKR, Intesa to pool together restructured loans, Reuters says
Subscribe for More Information
April 8, 2015
08:58 EDTKKRKKR to surrender part of Maxeda, seeks $217M writeoff, Bloomberg says
Subscribe for More Information
April 7, 2015
07:14 EDTGSK, SNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use